1,720,997 research outputs found
CONTRIBUTION OF FETAL HLA-C LIGANDS AND MATERNAL KIR RECEPTORS IN THE EVOLUTION OF GESTATIONAL HYPERTENSION TO OVERT PREECLAMPSIA
No full textMesothelial cystic inclusion in mullerian septum of the uterus: aetpathogenesis and evolution in pregnancy
No full textPrevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline.
No full textTo evaluate the efficacy of a single oral administration of the new ergot derivative Cabergoline in the prevention of post-partum lactation, we compared the effects of three different doses of the drug with those of placebo in 32 puerperal women. In a controlled, double-blind trial, the subjects were randomly allocated to four treatment groups receiving either placebo or 400, 600, or 800 micrograms Cabergoline (N = 8 in each group) within 24 hours after delivery. Treatment efficacy was assessed clinically by physical examination before (day 0) and at one, two, three, four, and 14 days after treatment. Plasma prolactin (PRL) concentrations were measured in blood samples collected before and at one, two, three, and four days after treatment. Lactation was prevented in four of the eight subjects (50%) who received 400 micrograms Cabergoline and in all subjects who received 600 or 800 micrograms Cabergoline. By contrast, only one of the eight subjects (12.5%) receiving placebo showed no signs of spontaneous lactation within the 14 days after delivery. No effects of placebo administration on plasma PRL levels were observed. Plasma PRL concentrations were significantly reduced starting from one day after Cabergoline administration, however, and the amount of inhibition of PRL secretion induced by different doses of the drug was not statistically different. These preliminary data demonstrate that Cabergoline has a dose-related effect in the prevention of postpartum lactation, and milk secretion can be prevented completely by a single oral administration of 600 or 800 micrograms of the drug
Role of Breast Ultrasonography in the Diagnosis of Precocious Puberty
No full textThe aim of this study was to determine the role of ultrasound evaluation of breast
tissue, singularly and in a multivariate model, in the early differentiation between
incomplete precocious puberty (IPP) and complete precocious puberty (CPP). In a
retrospective analysis, we evaluated 52 girls (CPP in 26 cases and IPP in 26) aged
1.35 - 9.59 yrs (mean± SD 7.55±1.47 yrs). Diagnostic evaluation of pts included:
breast Tanner stage, bone age, FSH and LH response to LHRH, basal 17-β-estradiol
(E2), pelvic and breast ultrasound. Logistic regression models were fitted to
identify possible diagnostic factors for IPP (as compared to CPP). All variables
with a p-value<0.1 at univariate analysis were included in a multivariate model to
assess their independent prognostic value. An additional model was fitted with
mammal gland volume forced into the model, due to its clinical relevance. The
area under the model ROC curve (AUC) was computed to assess model discrimination.
The data indicate that in our pts uterine volume ≥ 5cc, LH peak ≥7UI/L and
breast volume ≥ 1,1cc are hightly associated to CPP, bone age >2DS and E2 level
≥ 15μg/ml are only marginally associated, while FSH peak ≥10UI/L and diameter
of the dominant follicle ≥ 1cm are not associated . Uterine volume, LH peak, bone
age and diameter of the dominant follicle were included in a multivariate model,
that showed an independent prognostic role of uterine volume and LH peak. The
model had a high discriminant ability (AUC ROC 0.89) and permits to classify
correctly 77.78% of cases. When adding breast volume to model, this also proved
independent prognostic role for IPP, with further increase in discriminating ability
(AUC ROC 0.91). This second model permits to classify correctly 82.22% of
cases, so leading to better discrimination between IPP and CPP
Association between previously unknown connective tissue disease and subclinical hypothyroidism diagnosed during first trimester of pregnancy
No full textCombined use of goserelin acetate and human menopausal gonadotropin in the induction of follicular growth in a program of fertilization in vitro and embryo transfer
No full textOBJECTIVE: to investigate the efficacy of a gonadotropin-releasing hormone analogue (GN-RH-a) in combination with human menopausal menotropin (hMG) for in-vitro fertilization.
METHODS: 30 infertile women aged 32 to 37 years received a combined treatment with a long-acting slow-releasing Gn-RH-a and hMG to perform ovarian stimulation in a program of in-vitro fertilization. Serum levels of Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), 17-beta-estradiol (E2), Progesterone (P), were evaluated and transvaginal ultrasonographic examinations were performed during the treatment to assess the ovarian volume, the mean number and diameter of growing follicles and the endometrial morphology and thickness. Oocyte retrieval was performed by transvaginal-ultrasound-guided approach, 24-36 hours after the administration of human chorionic gonadotropin (hCG).
RESULTS: our data suggest that the combined use of Gn-RH-a and exogenous gonadotropins is associated with a more uniform ovarian response and with the absence of premature LH discharge. Moreover, the Gn-RH-a as polymer implant provides a controlled delivery per day over a one-month period and avoids the inconvenience of a daily administration.
CONCLUSIONS: this kind of Gn-RH-a formulation, in in-vitro fertilization programs, appears very effective in inducing a reversible hypogonadic state, easy to manage and well tolerated by the patient. Its association with exogenous gonadotropins appears to be effective in increasing the success rate of good quality oocyte retrieva
- …
